These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

879 related items for PubMed ID: 20974317

  • 1. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J.
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [Abstract] [Full Text] [Related]

  • 2. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC.
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [Abstract] [Full Text] [Related]

  • 3. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A.
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [Abstract] [Full Text] [Related]

  • 4. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S, Imagawa T, Mori M, Miyamae T, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [Abstract] [Full Text] [Related]

  • 5. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M, Östör A.
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [Abstract] [Full Text] [Related]

  • 6. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF, Qushmaq K, Aljishi F.
    Ann Saudi Med; 2016 Mar; 36(3):190-6. PubMed ID: 27236390
    [Abstract] [Full Text] [Related]

  • 7. Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
    Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A, MUSASHI Study Investigators.
    J Rheumatol; 2015 May; 42(5):799-809. PubMed ID: 25834203
    [Abstract] [Full Text] [Related]

  • 8. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.
    Mod Rheumatol; 2010 Aug; 20(4):343-52. PubMed ID: 20480201
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Sigaux J, Hamze M, Daien C, Morel J, Krzysiek R, Pallardy M, Maillere B, Mariette X, Miceli-Richard C.
    Joint Bone Spine; 2017 Jan; 84(1):39-45. PubMed ID: 27369643
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ.
    Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
    [Abstract] [Full Text] [Related]

  • 11. [Tocilizumab in rheumatoid arthritis].
    Rueda Gotor J, Blanco Alonso R.
    Reumatol Clin; 2011 Mar; 6S3():S29-32. PubMed ID: 21794769
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 13. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE.
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
    [Abstract] [Full Text] [Related]

  • 14. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
    Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC.
    Arthritis Care Res (Hoboken); 2013 Mar; 65(3):362-71. PubMed ID: 22972745
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
    Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Bao M, Rowell L, Davies C, Mysler EF.
    Ann Rheum Dis; 2016 Jan; 75(1):68-74. PubMed ID: 26056119
    [Abstract] [Full Text] [Related]

  • 16. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
    Navarro-Millán I, Singh JA, Curtis JR.
    Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.
    Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.
    Clin Rheumatol; 2019 Sep; 38(9):2411-2421. PubMed ID: 31028551
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T, Fujio K, Yamaoka K, Tomobe M, Kuroyanagi K, Kameda H.
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.